BRAF Targets in Melanoma: Biological Mechanisms, Resistance, and Drug Discovery
Author:   Ryan J. Sullivan
Publisher:   Humana Press Inc.
Edition:   Softcover reprint of the original 1st ed. 2015
Volume:   82
ISBN:  

9781493953486


Pages:   204
Publication Date:   10 September 2016
Format:   Paperback
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Our Price $290.37 Quantity:  
Add to Cart

Share |

BRAF Targets in Melanoma: Biological Mechanisms, Resistance, and Drug Discovery


Add your own review!

Overview

Full Product Details

Author:   Ryan J. Sullivan
Publisher:   Humana Press Inc.
Imprint:   Humana Press Inc.
Edition:   Softcover reprint of the original 1st ed. 2015
Volume:   82
Dimensions:   Width: 15.50cm , Height: 1.10cm , Length: 23.50cm
Weight:   3.285kg
ISBN:  

9781493953486


ISBN 10:   1493953486
Pages:   204
Publication Date:   10 September 2016
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Melanoma: Historical Context.- Melanoma Pathogenesis.- Molecular Diagnostics and Tumor Mutational Analysis.- Clinical Utility of BRAF-targeted therapy in Melanoma.- The Ethics of Randomized Trials in Oncology.- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma.- Targeting the cell cycle and p53 in combination with BRAF-directed therapy.- Combination BRAF-directed therapy and immunotherapy.- Moving Forward: Making BRAF-Targeted Therapy Better.

Reviews

Author Information

Dr. Ryan J. Sullivan is affiliated with Massachusetts General Hospital and Dana Farber. His research interests are in the development of novel molecular therapeutic agents for Kaposi sarcoma (KS) and malignant melanoma and the translation of promising preclinical findings into early stage clinical trials. He serves as the co-director of the Eugene Michael Egan Melanoma Translational Research Laboratory at Beth Israel Deaconess Medical Center (BIDMC) and is actively investigating promising biomarkers of response and benefit to immunotherapy and molecular targeted therapy for patients with melanoma.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

MRG2025CC

 

Shopping Cart
Your cart is empty
 Shopping cart
Mailing List

 

Sign up now